Omeros Corporation OMER

Omeros Corporation es una empresa biofarmacéutica en fase clínica. Está enfocada en descubrir, desarrollar y comercializar terapias con moléculas pequeñas y proteínas para mercados grandes y enfermedades huérfanas que afectan a trastornos inmunológicos, incluyendo enfermedades mediadas por el complemento, cánceres y trastornos adictivos y compulsivos. Su inhibidor principal de MASP-2, narsoplimab, se enfoca en la vía de lectina del complemento y es objeto de una solicitud de licencia biológica para el tratamiento de microangiopatía trombótica asociada al trasplante de células madre hematopoyéticas. Narsoplimab también se encuentra en múltiples programas de desarrollo clínico avanzado enfocados en otros trastornos mediados por el complemento, incluyendo la nefropatía IgA, COVID-19 y el síndrome urémico hemolítico atípico. OMS906, su inhibidor de MASP-3, el activador clave de la vía alternativa del complemento, está avanzando en programas clínicos para la hemoglobinuria paroxística nocturna, la glomerulopatía del complemento 3 (C3) y una o más indicaciones relacionadas.

• GlobeNewswire Inc. 28 jul

  INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

  Pomerantz LLP is investigating potential securities fraud claims against Omeros Corporation following the company's announcement on June 26, 2026, that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion on the marketing authorization application for narsoplimab for treating TA-TMA. The negative regulatory decision triggered a 19.12% stock price decline, falling $2.05 per share to $8.67.

  

• GlobeNewswire Inc. 21 jul

  INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER

  Pomerantz LLP is investigating potential securities fraud claims against Omeros Corporation following the company's announcement of a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use on its marketing authorization application for narsoplimab. The news triggered a 19.12% stock price decline on June 26, 2026.

  

• GlobeNewswire Inc. 13 jul

  Omeros Corporation Investigated by the Portnoy Law Firm

  The Portnoy Law Firm has initiated an investigation into possible securities fraud at Omeros Corporation following the European Medicines Agency's negative opinion on the company's narsoplimab marketing authorization application on June 26, 2026. The negative regulatory decision triggered a 19.12% stock price decline, dropping from $10.72 to $8.67 per share. The firm is seeking to file a class action lawsuit on behalf of affected investors.

  

• The Motley Fool 8 jul

  Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?

  Heartflow, an AI-driven diagnostic platform, shows strong 40% revenue growth but faces reimbursement headwinds and remains unprofitable. Omeros is transitioning to commercial stage with its newly approved drug Yartemlea, posting early Q1 2026 revenue of $9.89 million. The article recommends Omeros as the safer bet for 2026 despite trading at a premium, citing its transition to profitability versus Heartflow's expected positive free cash flow not until 2028.

  

• The Motley Fool 20 jun

  Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

  The article compares two emerging biotech stocks: Intellia Therapeutics, which focuses on CRISPR gene-editing technology with promising Phase III trial data but significant losses and clinical risks, and Omeros, which recently achieved FDA approval for Yartemlea and posted its first commercial revenue of $9.89 million. While Intellia offers higher upside potential, Omeros is deemed the safer choice due to its transition to profitability, strong initial sales, and healthier balance sheet, despite trading at a premium valuation.